Midostaurin

Midostaurin
Clinical data
Trade names	Rydapt
Other names	PKC412, 4'-N-benzoylstaurosporine
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
ATC code	L01EX10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiamzonine-1-one;
CAS Number	120685-11-2;
PubChem CID	9829523;
IUPHAR/BPS	5702;
DrugBank	DB06595;
ChemSpider	8005258;
UNII	ID912S5VON;
KEGG	D05029;
ChEMBL	ChEMBL608533;
CompTox Dashboard (EPA)	DTXSID40923522 ;
Chemical and physical data
Formula	C35H30N4O4
Molar mass	570.649 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC;
	InChI InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1; Key:BMGQWWVMWDBQGC-IIFHNQTCSA-N;

Midostaurin, sold under the brand name Rydapt by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.

^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^ "Rydapt EPAR". European Medicines Agency. 18 September 2017. Retrieved 29 June 2024.
^ New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.